Form 4 for TNGX Tango Therapeutics, Inc.
Accepted 2026-02-04 00:00:00 ET · period of report 2026-02-02 · accession 0001193125-26-038070 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-04 | 2026-02-03 | TNGX | Weber Barbara | Dir, Executive COB | S - Sale | $12.27 | -30.5K | 1.63M | -2% | -$374.4K |
| D | 2026-02-04 | 2026-02-02 | TNGX | Weber Barbara | Dir, Executive COB | A - Grant | $0.00 | +37.5K | 1.66M | +2% | $0 |
| D | 2026-02-04 | 2026-02-02 | TNGX | Weber Barbara | Dir, Executive COB | A - Grant | $0.00 | +222.1K | 222.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-03 | S | D | 333 | $12.90 | 1,629,254 | D | — | — | (F4) Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 2 | Common | Common Stock | 2026-02-03 | S | D | 30,186 | $12.26 | 1,629,587 | D | — | — | (F3) Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 3 | Common | Common Stock | 2026-02-02 | A | A | 37,522 | $0.00 | 1,659,773 | D | — | — | (F1) These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in full on February 1, 2027, subject to the Reporting Person's continuous service with the Issuer as of such vesting date. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-02-02 | A | A | 222,132 | $0.00 | 222,132 | D | $11.94 · — to 2036-02-02 | 222,132 Common Stock | (F5) This option shall vest and become exercisable in 12 equal monthly installments following January 1, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. |